西达本胺在外周T细胞淋巴瘤维持治疗中的有效性及安全性
华 尹, 金花 梁, 佳竹 吴, 悦 李, 馨予 张, 祎琳 孔, 必慧 潘, 莉 王, 建勇 李, 卫 徐, 浩睿 申 · 2024
Read 西达本胺在外周T细胞淋巴瘤维持治疗中的有效性及安全性 by 华 尹, 金花 梁, 佳竹 吴, 悦 李, 馨予 张, 祎琳 孔, 必慧 潘, 莉 王, 建勇 李, 卫 徐, 浩睿 申 (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11886691.txt.
Description
Yin Hua and co-authors reviewed a maintenance drug for a hard lymphoma in a 2024 study from a Nanjing hospital. Peripheral T-cell lymphoma is an aggressive blood cancer with few good options after first treatment. Keeping the disease quiet with a gentler maintenance drug could extend remission.
The team looked back at fifty-eight patients treated since 2015 and assessed how well the drug worked and how safe it was as maintenance therapy. Retrospective series like this one are often the first evidence for maintenance strategies in rare lymphomas. If the benefit holds, randomized trials can follow. For patients facing relapse, even modest extra time in remission carries real weight in daily life.
Catalog record
| CREATOR | 华 尹, 金花 梁, 佳竹 吴, 悦 李, 馨予 张, 祎琳 孔, 必慧 潘, 莉 王, 建勇 李, 卫 徐, 浩睿 申 |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |